Beranda › Kanker Kandung Kemih › Ohio › Columbus
Uji klinis Kanker Kandung Kemih di Columbus, OH
19 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Columbus (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Menerima pesertaFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- dan 8 lainnya
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Menerima pesertaFase 2
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- dan 1 lainnya
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- dan 11 lainnya
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Menerima pesertaFase 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Menerima pesertaFase 1
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Menerima pesertaFase 2
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · 7 mi jauhnya
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- The Ohio State University (OSU), Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Menerima pesertaFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Menerima pesertaFase 1/2
- Central Ohio Urology Group, Gahanna · 7 mi jauhnya
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Menerima pesertaStudi observasional
- The Ohio State University, Columbus
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Menerima pesertaFase 2/3
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Menerima pesertaFase 2
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- dan 2 lainnya
Blue Light Cystoscopy With Cysview® Registry
Menerima pesertaStudi observasional
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Columbus
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Dallas, TX27 studi
- Boston, MA26 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
Studi lain di Columbus
- Kanker Paru Non-Sel Kecil56 studi
- Kanker Payudara39 studi
- Kanker Ovarium39 studi
- Kanker (semua jenis)38 studi
- Kanker Paru37 studi
- Leukemia Mieloid Akut35 studi
- Leukemia Limfositik Kronis28 studi
- Kanker Metastatik27 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal24 studi
- Kanker Prostat24 studi
- Mieloma Multipel24 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.